Colorectal Cancer Clinical Trial
Official title:
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer (CEPO906AUS10)
This study is for people with advanced colorectal cancer. This study uses the drugs Celebrex
and EPO906. EPO906 is an experimental drug that has not been approved by the FDA. EPO906 is
a drug that has been shown in the laboratory to cause cancer cells to die and prevents them
from growing and reproducing. Celebrex is a drug that is approved by the FDA for the
treatment of arthritis and prevention of colon polyps. Colon polyps are small growths in the
colon. If not surgically removed, some colon polyps can become cancerous. Some studies have
shown that Celebrex may reduce the side effects of chemotherapy. Other studies have shown
that it may increase the effectiveness of some chemotherapy. Celebrex is not approved by the
FDA for reducing the side effects of chemotherapy or improving the effectiveness of
chemotherapy. The combination of EPO906 and Celebrex in this study is experimental.
The main goal of this study is to see if adding the drug Celebrex to the drug EPO906 will
decrease the amount of diarrhea seen in patients that receive EPO906.
The goal of the first phase of this study is to find the highest dose of EPO906 that can be
given safely with Celebrex. The dose of Celebrex will remain the same for the whole study.
Higher doses of EPO906 will be given to each group of patients. The increase of EPO906 will
stop once more than one patient has serious side effects. The highest dose of EPO906 that
can be given with Celebrex (without serious side effects) will be called the pilot dose.
The goal of the second phase of this study is to find out how tumors respond to these doses
of the drugs. Another purpose of this study is to see how the body processes the EPO906 and
Celebrex. This study will also look at the side effects of these drugs. In this study, we
will measure how long subjects live, how often tumors shrink after receiving the study
drugs, and how long it takes for tumors to increase in size after receiving the study drugs.
This study will also measure the levels of genes, which are the cell's blueprint, in
participant's tumors. Several genes can affect how people's bodies react to the cancer
drugs. Genes will also be measured in participant's blood. We want to see if these predict
response to the study drugs.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |